• Alias: MK 0683: SAHA
    • An orally available, synthetic hydroxamic acid derivative that binds to the catalytic domain of the HDACs, allowing the hydroxamic moiety to chelate zinc ion, thereby inhibiting deacetylation and leading to an accumulation of both hyperacetylated histones and transcription factors
    • FDA approved for CTCL that is progressive, persistent, or recurrent after two lines of treatment
    • Dose: 400 mg PO daily with food. Take with plenty of water and keep hydrated.
    • Half-life: â™2 hours
    • Side effects: Fatigue, peripheral edema, alopecia, nausea/diarrhea, pruritus, hyperglycemia, proteinuria
    Other topics in Targeted and Immunotherapy Agents